TNFSF10 and cancer: The inability to effectively target BCL-2 proteins accounts for resistance to bortezomib [153,154,155], rapamycin [156], cyclin-dependent kinase inhibitors [157], ABT 737 [158], and death receptor (Fas/TRAIL)-induced apoptosis [106] in various cancers including MM.